After Eli Lilly launched Mounjaro in India — a GLP-1 drug for treating diabetes and obesity, Zerodha’s Nithin Kamath remarked that people all over the world do not fully comprehend the long-term impact of these drugs.
“What we don't know is more than what we know about these drugs at this point,” he shared.
What is Mounjaro?
Mounjaro, which contains tirzepatide, imitates a hormone that regulates blood sugar levels and appetite.
Though originally developed for diabetes, the drug has shown weight-loss benefits — allowing users to shed 15–20% of their body weight.
However, a single-dose vial costs ₹3,500 for 2.5 mg or ₹4,375 for 5 mg. On a typical weekly dose, that could be over ₹2 lakh a year.
Zerodha's Nithin Kamath comments about new weight loss drug
“People will eat less, smoke less, buy less, and live longer. They’ll also trade less? Insurance premiums have to change, and annuity payouts in pensions will have to be readjusted,” Nithin Kamath wrote, indicating the effects these drugs could trigger.
Early reports suggest that GLP-1 drugs go well beyond weight. According to reports, it reduces cravings linked to alcohol, nicotine, gambling, and even compulsive shopping.
Some studies suggest benefits for cardiovascular health, dementia, Alzheimer’s, and mental health.
The Zerodha boss said, “Even if half of what's being reported is true, then this will be the closest thing we've seen to a miracle drug.”
Also read: 'Career Or Business–It’s A Marathon Race': Thyrocare Founder Dr A. Velumani (startuppedia.in)
/startuppedia/media/media_files/2025/03/24/ELWu8SHjhQiu94Da3fsO.jpeg)